Introducing Pulmolisa, a simple blood test for the early detection and differential diagnosis of lung cancer developed by Biosystems Immunolab.
Biosystems Immunolab is an in-vitro diagnostics R&D company delivering solutions for the early detection of cancer using its protected protein epitome profiling technology platform for the discovery and development of disease-specific plasma protein epitope panels (multivariate index assays) that can be run on popular validated protein array and ELISA platforms. Pulmolisa is our first product.
Our mission: To improve health by the timely detection of cancer and treatment of inflammatory diseases.
Protein Atlas (https://www.proteinatlas.org) finds strong correlation of a histidine rich glycoprotein (HRG; Uniprot ID: P04196; NCBI Gene ID: 3273; Omim ID: 142640) blood plasma epitope level detected by the BSI0137 mAb with HDL, LDL, Triglyceride and Total Cholesterol levels. Hong MG, Dodig-Crnković T, Chen X, Drobin K, Lee W, Wang Y, Edfors F, Kotol D, Thomas CE, Sjöberg R, Odeberg J., Hamsten … Continue reading Protein Atlas
Collaboration with Ambrichor
Collaboration with Ambrichor: Ambrichor Zrt and Biosystems Immunolab Zrt. signs a collaboration agreement to develop lung cancer screening for blood collection and storage centers and blood donors who are at high risk of developing lung cancer.
Biosystems Immunolab obtains venture capital investment from Bonitás Venture Capital Fund, Fastventures, Ambrichor, and a private investor for the commercialization and further clinical testing of Pulmolisa, Biosystems’ lung cancer test.